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BACKGROUND
Many patients living with HIV (PLWH) experience 
chronic pain from a variety of etiologies and 
 utilize prescribed opioids for pain management. 
Opioid prescriptions surged in the US from the 
late 1990s through the early-2010s with con-
current increases in fatal overdoses attributable 
to opioid use (both prescription and illicit). The 
2016 CDC guidelines questioned the efficacy 
and safety of chronic opioid therapy, highlighting 
the paucity of data demonstrating efficacy of 
long-term prescription opioid use and stressing 
the risks associated with higher dose therapy 
(>90 morphine milligram equivalents per day 
(MME)), particularly unintentional overdose and 
death. The guidelines called for changes in 
 clinician behaviors and prescribing patterns to 
more safely manage chronic pain, particularly  
in reducing the frequency, dosage and duration 
of opioid prescriptions. 
SUMMARY OF PROCESS
In response to the CDC recommendations, we 
examined our practice’s prescribing patterns and 
sought to improve patient safety through a two-phase 
initiative de-emphasizing prescription opioids for 
chronic pain and reducing opioid doses in a 
supportive, trauma-informed manner. Throughout, we 
focused on managing the multifaceted suffering that 
occurs in the setting of chronic pain in PLWH:
Phase 1 (12/2016): Distribute unblinded dashboard 
of all patients on opioid therapy including total daily 
dose (in MME) and provider, update patient charts to 
discontinue completed short-term opioid courses, 
verify appropriateness of chronic opioid use, and 
update opioid treatment agreements to include 
random drug screens/pill counts. State PDMP 
became available in 2017.
Phase 2 (10/2017): Begin multidisciplinary case 
reviews for patients taking >50 MME with provider, 
nurse, and behavioral change specialists to establish 
trauma-informed strategies for dose reduction and 
symptom management. Management of comorbid 
behavioral health disorders and emotional support 
was addressed. Management plans for potential 
relapse in those with history of substance use  
were discussed along with emergency naloxone 
education/prescription.
DISCUSSION
•  Our experience demonstrates that meaningful 
reductions in prescribed opioids can be 
achieved through a supportive, trauma-
informed, team-based approach without 
raising the incidence of relapse to illicit  
opioid use.  
•  Our model was successful in changing 
provider opioid prescribing behaviors as 
demonstrated in the sustained reductions 
observed for all providers in the practice.  
•  Lower dose opioid therapy should improve the 
safety of pain management in PLWH by 
reducing risk of overdose and death.  
•  Future work will continue to focus on patients 
taking >50 MME and also address con -
current use of high risk medications such  
as benzodiazepines, sedative hypnotics and 
muscle relaxers.
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Figure 1: Decline in total prescribed opioid dose for all providers 










Practice-wide Opioid Prescribing by MME Risk Range
■MME >90   ■MME 50–89   ■MME <50
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OUTCOMES
•  At baseline, 30 patients were taking >90 MME 
for a total of 10,360 MME (68.5% of total 
practice dose). Five patients were taking >500 
MME (35% of total practice dose).
•  During the intervention, the number of patients 
taking any prescription opioid dropped from 175 
to 87 (-50.3%) in phase 1 and then to 58 patients 
(-33.3%) in phase 2, an overall decrease of 66.9%.
•  The total practice dose decreased from 15,116 
to 10,580 MME (-30.0%) in phase 1 and further 
to 8,306 MME (-21.5%) in phase 2 for an 
overall decrease of 6,810 MME (-45.1%).
•  Patients taking >90 MME decreased from 30 at 
baseline to 23 (-23.3%). This cohort also saw 
the largest overall dose reduction from 10,360 
to 6,750 MME (-34.8%). 
•  No known relapses of illicit opioid use occurred  
in patients initially receiving >50 MME who 
subsequently underwent dose reduction.
•  Patient satisfaction scores (CAHPS) were not 
impacted and are currently at an all-time high.
